Asciminib Mitigates DNA Damage Stress Signaling Induced by Cyclophosphamide in the Ovary

Cancer treatments can often adversely affect the quality of life young women. One most relevant negative impacts is loss fertility. Cyclophosphamide one detrimental chemotherapeutic drugs for ovary. may induce destruction dormant follicles while promoting follicle activation and growth. Herein, we demonstrate in vivo protective effect allosteric Bcr-Abl tyrosine kinase inhibitor Asciminib on signaling pathways activated by cyclophosphamide mouse ovaries. We also provide evidence that does not interfere with cytotoxic Michigan Foundation (MCF)7 breast cancer cells. Our data indicate concomitant administration mitigates cyclophosphamide-induced ovarian reserve without affecting anticancer potential cyclophosphamide. Taken together, these observations are development effective ferto-protective adjuvants to preserve from damaging effects therapies.